Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized placebo-controlled study of iptacopan in generalized myasthenia gravis with open-label extension
2023-507064-39-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing iptacopan with placebo (2 arms). Primary endpoint: Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living total score. Planned start Sep 2024; status: authorised.
02
Drugs
Iptacopan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2023-507064-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507064-39-00.